Align Technology Inc.
ALGNBusiness Overview
ticker: ALGN step: 01 generated: 2026-05-13 source: quick-research
Align Technology Inc. (ALGN) — Business Overview
Business Description
Align Technology is the creator of Invisalign clear aligners and the iTero intraoral scanner, dominating the digital orthodontics market it essentially invented in 1997. The company has treated over 20 million patients globally (as of Q1 2025), with a platform extending from clear aligner manufacturing through digital scanning (iTero) and CAD/CAM software (exocad). Align generates ~$4B in annual revenue across two segments: Clear Aligners (~81% of revenue) and Imaging Systems & CAD/CAM Services (~19%). Q1 2026 revenue grew 6.2% YoY.
Revenue Model
Clear Aligner revenue is driven by case submissions from orthodontists and dentists purchasing Invisalign treatment packages, with pricing varying by case type (comprehensive adult, teen, moderate, minor). Revenue is recognized when aligners ship. iTero scanner sales are direct hardware + software subscription revenue; iTero drives Invisalign adoption by integrating digital scanning directly into the ordering workflow. 70%+ gross margins reflect the proprietary manufacturing process and brand premium.
Products & Services
- Invisalign: Clear aligner system for comprehensive orthodontic treatment (adult and teen); also Vivera retainers
- Invisalign Go / Moderate: Shorter, simpler treatments for general dentists (not just orthodontists)
- iTero Lumina: Latest-generation intraoral scanner (launched March 2025); captures 3D tooth scans for orthodontic and restorative workflows
- exocad: CAD/CAM dental design software for lab and in-office crown/bridge workflows
- Invisalign Doctor Site: Digital platform for case submission, progress tracking, and clinical tools
Customer Base & Go-to-Market
Orthodontists and general dentists worldwide are the primary customers — Align markets heavily to dental professionals through direct sales reps, training programs ("Invisalign Go" expansion targeting GPs), and the Doctor Locator digital patient referral tool. Patient demand ("doctor influence" marketing) creates pull-through. Direct-to-consumer aligner companies (SmileDirectClub, now defunct) attempted to bypass the professional channel — Align's moat is the professional relationship.
Competitive Position
Align holds ~90%+ market share in clear aligners by revenue among professionally-dispensed systems. The key threats are 3M, Dentsply Sirona, and 3Shape in adjacent products, plus direct-to-consumer (mostly eliminated post-SmileDirectClub bankruptcy) and in-office 3D printing (emerging risk). Network effects (more orthodontists → more patient referrals → more training → more adoption) reinforce the moat. Elliott Management built an activist stake in 2025, pressuring management on execution.
Key Facts
- Founded: 1997
- Headquarters: Tempe, AZ
- Employees: ~21,000
- Exchange: NASDAQ
- Sector / Industry: Health Care / Health Care Equipment
- Market Cap: ~$11B
Financial Snapshot
ticker: ALGN step: 04 generated: 2026-05-13 source: quick-research
Align Technology Inc. (ALGN) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $3.73B | $3.86B | $4.00B | +3.5% |
| Gross Margin | ~70.7% | ~70.1% | ~70.0% | |
| Operating Margin | ~15% | ~12% | ~14% | |
| Net Income | ~$552M | ~$418M | $421M | +0.7% |
| EPS (diluted) | ~$7.10 | ~$5.55 | ~$5.65 | +1.8% |
Revenue growth has slowed dramatically from the COVID-era boom (~$4B peak in 2021, then $3.95B in 2022, then soft recovery). Clear aligner volumes grew 3.5% in 2024 to 2.5M cases. Q1 2026 revenue up 6.2% YoY; Q4 2025 record 676.9k cases (+7.7% YoY).
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$700M |
| Free Cash Flow | ~$500M |
| Capital Expenditures | ~$200M |
| Cash & Equivalents | ~$800M |
| Total Debt | Minimal (net cash position) |
Key Ratios (approximate)
- P/E: ~20-22x | EV/EBITDA: ~15x | FCF Yield: ~4.5%
- Gross Margin: ~70% (industry-leading for MedTech)
- Net Cash Position: Positive; recently announced $200M share repurchase (Q1 2026)
Growth Profile
Align's revenue growth slowed from 60%+ pandemic-era peaks to mid-single digits (3-4% annually) as pent-up demand normalized. The global clear aligner penetration rate remains extremely low (~5-8% of orthodontic cases use clear aligners), suggesting a multi-decade runway. Key growth vectors: (1) expanding Invisalign Go into general dentistry, (2) teens/kids market (5.8M treated to date), (3) international markets (Europe, LATAM, APAC showing stronger growth than U.S.), (4) iTero Lumina scanner cycle driving case submission growth.
Forward Estimates
- FY2026 Guidance: Revenue growth 3-4%; operating margins ~14-16%; $200M buyback
- FY2026 Q1 actual: Revenue $979.3M (+6.2% YoY); beat estimates; reaffirmed guidance
- Analyst consensus: Moderate Buy; avg. target ~$186 (range $140-$220)
- Elliott Management activist involvement: pressure on cost structure and capital allocation
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $ALGN.